KYMR Kymera Therapeutics, Inc.
Stock · NasdaqGM · United States · Healthcare · US5015751044
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Kymera Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
131.73 USD
+2.82%
52-week range
56.75 – 138.00
Dividend yield—
Market cap10.9B
NowoTrade score
0 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:09. Information, not advice.
Results
Next results
25 Feb 2027
in 110 days · 08:00 · estimate -1.26
Last results
-1.32 vs -1.27 estimated
29 Oct 2026 · Miss -4.3%
Beat the estimate
7 of 12
5 missed · 0 in line
Average surprise
+1.8%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 08:00 | -1.26 | — | — | Upcoming |
| 29 Oct 2026 07:00 | -1.27 | -1.32 | -4.3% | Miss |
| 05 Aug 2026 07:00 | -0.74 | -0.62 | +16.0% | Beat |
| 30 Apr 2026 07:00 | -0.86 | -0.71 | +17.1% | Beat |
| 26 Feb 2026 07:00 | -0.77 | -0.98 | -27.1% | Miss |
| 04 Nov 2025 07:00 | -0.78 | -0.94 | -20.3% | Miss |
| 11 Aug 2025 07:00 | -0.80 | -0.95 | -19.1% | Miss |
| 09 May 2025 07:00 | -0.91 | -0.82 | +9.9% | Beat |
| 27 Feb 2025 07:00 | -0.79 | -0.89 | -12.9% | Miss |
| 31 Oct 2024 07:00 | -0.84 | -0.82 | +2.9% | Beat |
| 07 Aug 2024 07:00 | -0.66 | -0.58 | +12.0% | Beat |
| 02 May 2024 07:00 | -0.72 | -0.62 | +14.0% | Beat |
| 22 Feb 2024 07:00 | -0.38 | -0.25 | +33.6% | Beat |
| 02 Nov 2023 07:00 | -0.70 | -0.90 | -29.4% | Miss |
| 03 Aug 2023 07:00 | -0.74 | -0.67 | +9.2% | Beat |
| 04 May 2023 07:00 | -0.69 | -0.70 | -1.0% | In line |
| 23 Feb 2023 07:00 | -0.63 | -0.59 | +6.9% | Beat |
| 03 Nov 2022 07:00 | -0.75 | -0.79 | -5.9% | Miss |
| 09 Aug 2022 07:00 | -0.69 | -0.78 | -13.2% | Miss |
| 03 May 2022 07:00 | -0.67 | -0.71 | -6.3% | Miss |
| 24 Feb 2022 07:00 | -0.57 | -0.67 | -18.0% | Miss |
| 10 Nov 2021 07:00 | -0.37 | -0.56 | -52.0% | Miss |
| 06 Aug 2021 07:00 | -0.25 | -0.55 | -122.4% | Miss |
| 06 May 2021 07:00 | -0.20 | -0.29 | -46.8% | Miss |
| 11 Mar 2021 07:00 | -0.14 | -0.29 | -103.5% | Miss |
| 05 Nov 2020 07:00 | 2.91 | -0.39 | -113.4% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 39.2M | -16.7% | -311.4M | -794.0% | -3.69 | -23.8% | -234.3M |
| 2024 | 47.1M | -40.1% | -223.9M | -475.6% | -2.98 | -18.3% | -207.3M |
| 2023 | 78.6M | +67.8% | -147M | -187.0% | -2.52 | +12.2% | -137.3M |
| 2022 | 46.8M | — | -154.8M | -330.6% | -2.87 | — | -155.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 27 Jul 2022 | 22.48 | 23.35 | 21.65 | 22.86 | +3.21% | 775,900 | |
| 26 Jul 2022 | 20.80 | 23.02 | 20.43 | 22.15 | +5.93% | 476,000 | |
| 25 Jul 2022 | 21.73 | 21.73 | 20.33 | 20.91 | -3.68% | 332,800 | |
| 22 Jul 2022 | 22.92 | 23.28 | 21.50 | 21.71 | -4.57% | 578,100 | |
| 21 Jul 2022 | 23.26 | 23.62 | 22.58 | 22.75 | -2.53% | 710,000 | |
| 20 Jul 2022 | 22.90 | 23.96 | 22.31 | 23.34 | +1.97% | 751,300 | |
| 19 Jul 2022 | 21.30 | 22.90 | 21.01 | 22.89 | +8.74% | 928,300 | |
| 18 Jul 2022 | 23.78 | 24.21 | 21.00 | 21.05 | -9.38% | 751,100 | |
| 15 Jul 2022 | 24.31 | 24.47 | 22.31 | 23.23 | -3.09% | 557,600 | |
| 14 Jul 2022 | 23.97 | 24.71 | 23.53 | 23.97 | -0.58% | 445,500 | |
| 13 Jul 2022 | 22.32 | 24.32 | 22.02 | 24.11 | +5.56% | 425,900 | |
| 12 Jul 2022 | 24.07 | 24.10 | 21.66 | 22.84 | -4.55% | 654,000 | |
| 11 Jul 2022 | 25.94 | 25.94 | 23.47 | 23.93 | -9.22% | 831,700 | |
| 08 Jul 2022 | 25.02 | 26.45 | 24.56 | 26.36 | +4.15% | 446,800 | |
| 07 Jul 2022 | 23.74 | 25.40 | 23.70 | 25.31 | +7.29% | 661,400 | |
| 06 Jul 2022 | 23.70 | 25.15 | 23.41 | 23.59 | -0.30% | 588,000 | |
| 05 Jul 2022 | 20.60 | 23.69 | 20.29 | 23.66 | +12.13% | 712,200 | |
| 01 Jul 2022 | 19.58 | 21.26 | 18.90 | 21.10 | +7.16% | 582,800 | |
| 30 Jun 2022 | 19.82 | 20.23 | 18.98 | 19.69 | -2.96% | 632,000 | |
| 29 Jun 2022 | 19.60 | 20.56 | 19.34 | 20.29 | +3.15% | 516,100 | |
| 28 Jun 2022 | 20.69 | 21.12 | 19.26 | 19.67 | -5.11% | 831,000 | |
| 27 Jun 2022 | 20.10 | 21.21 | 19.54 | 20.73 | +2.98% | 639,000 | |
| 24 Jun 2022 | 19.66 | 20.24 | 18.37 | 20.13 | +2.70% | 2,093,300 | |
| 23 Jun 2022 | 17.72 | 19.68 | 17.72 | 19.60 | +10.80% | 758,300 | |
| 22 Jun 2022 | 16.58 | 18.54 | 16.40 | 17.69 | +3.81% | 653,200 |
Page 44 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Kymera Therapeutics (KYMR) Stock May Be Overvalued Following Positive KT 579 Data (opens in a new tab) Simply Wall St. · 05 Nov 2026 12:18
- Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170 (opens in a new tab) Benzinga · 02 Nov 2026 16:46
- Kymera Therapeutics, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 29 Oct 2026 22:53
- Kymera (KYMR) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 29 Oct 2026 20:44
- Kymera Therapeutics Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 29 Oct 2026 18:14
- Kymera Therapeutics (KYMR) Nears Earnings With KT 621 In Focus, Is The Stock Still Cheap? (opens in a new tab) Simply Wall St. · 27 Oct 2026 22:16
- Could You Have Seen The Run In Kymera Stock Coming? (opens in a new tab) Trefis · 26 Oct 2026 21:34
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? (opens in a new tab) Zacks · 19 Oct 2026 14:08
- Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (opens in a new tab) Zacks · 04 Sep 2026 16:30
- Can KT-621 Mark a Turning Point for Kymera Therapeutics? (opens in a new tab) Zacks · 03 Sep 2026 16:50
- Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says (opens in a new tab) MT Newswires · 02 Sep 2026 15:59
- Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 12 Aug 2026 18:14
- KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments (opens in a new tab) Zacks · 06 Aug 2026 19:52
- Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR) (opens in a new tab) Simply Wall St. · 06 Aug 2026 08:15
- Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Aug 2026 23:01
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 128.12 USD
- Market cap
- 10.9B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 2.6 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 6.6 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -933.9× the interest
- The last full year was a loss
- Revenue has fallen two years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -26.16× | Weak | 14.98× |
| Price / book | 6.96× | Weak | 3.87× |
| Price / sales | 110× | Weak | 3.37× |
| EV / EBITDA | -25.21× | Weak | 12.96× |
| Free cash flow yield | -1.5% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 59.2% |
| Operating margin | -396% | Weak | 7.4% |
| Net margin | 0% | Weak | 3.4% |
| Return on equity | -27.3% | Weak | 5.7% |
| Return on assets | -17.6% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -5.7% | Weak | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.05× | Good | 0.46× |
| Interest cover | -933.9× | Weak | 3.26× |
| Current ratio | 11.13× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow KYMR and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.